S&P 50 · Free
Johnson & Johnson
JNJ#PharmaceuticalsHigh stock comp
Johnson & Johnson trades at 20.74x forward earnings — 95% above peers (vs 7 peers in #Pharmaceuticals). Price $262.37.
- Forward P/E
- 20.74
- Industry median 10.64
- Current P/E
- 24.16
- Industry median 11.09
- Forward PEG
- 1.83
- Next fiscal year
- Opportunity Score
- 17
- Below average
Forward P/Edivides today's price by the earnings analysts expect Johnson & Johnson to make over the next fiscal year — see what forward P/E measures for the full definition. Opportunity Score is a separate, slower 0–100 read on how attractive today looks as a historical entry point — see how it's built.
Consensus earnings run well above GAAP earnings, mostly through stock-based compensation. Ordinary for high-growth software, but it dilutes shareholders and makes any single earnings multiple a weaker signal.